Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?

Table 3 Survival analysis

	Univariate		Multivariate
	P value	OR (95%CI)	P value	OR (95%CI)
Date of recurrence	0.006	1.00 (1.00-1.00)	0.79
Age at recurrence (years)	0.93
Time from transplant	< 0.001	0.977 (0.966-0.988)	0.001	0.977 (0.963-0.991)
Number of tumours	< 0.001	1.01 (1.01-1.02)	0.33
Size of largest tumour	0.02	1.11 (1.02-1.20)	0.02	1.13 (1.02-1.24)
Number of organs involved	0.01	1.14 (1.11-1.89)	0.27
Site of recurrence
Liver	0.01	1.62 (1.13-2.31)	0.01	1.92 (1.14-3.25)
Lung	0.43
Bone	0.17
Peritoneal	0.46
Adrenal	0.52
Lymph node	0.49
AFP upon recurrence	0.02	1.00 (1.00-1.00)	0.02	1.00 (1.00-1.00)
Immunosuppression after recurrence
mTOR inhibitor	< 0.001	0.485 (0.339-0.695)	0.04	0.482 (0.241-0.966)
Calcineurin Inhibitor	0.07
Tacrolimus trough (μg/L)	0.002	1.13 (1.04-1.22)	0.16
Treatment
Surgery	< 0.001	0.380 (0.240-0.601)	0.22
RFA	0.16
TACE	0.32
Radiotherapy	0.90
Targeted therapy	0.97
Immunotherapy	0.80
Supportive	< 0.001	2.34 (1.49-3.67)	0.73

AFP: Alpha-fetoprotein; RFA: Radiofrequency ablation; TACE: Trans-arterial chemoembolization; mTOR: Mammalian target of rapamycin.